Research Study

A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia
Principal Investigator 
York Hsiang

Overview

Body Locations and Systems 
Peripheral Arterial Disease
ClinicalTrials.gov# 
NCT02140931
Status 
Closed to Recruitment
Study Start/End 
Jul 16, 2014 to Dec 31, 2016
Locations 
Vancouver General Hospital
Name/Title 
Lynn Cunada, Study Coordinator
Phone 
604-875-5077
Purpose of Study 

A randomized, double-blind placebo controlled study to determine the safety and efficacy of Angiogenic Cell Precursors (ACPs) in relieving symptoms of Critical Limb Ischemia in patients treated with standard of care and with no surgical revascularization option. It is assumed that the ACP-treated group will have a lower amputation and death rate as compared to the placebo group. Other hemodynamic, imaging and clinical parameters will also be compared between the two groups. Quality of life assessments will also be performed.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.